140 related articles for article (PubMed ID: 30173128)
1. The changing face of cancer treatments.
Keohane D; Fitzgerald GP
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173128
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
4. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Crinò L; Bronte G; Bidoli P; Cravero P; Minenza E; Cortesi E; Garassino MC; Proto C; Cappuzzo F; Grossi F; Tonini G; Sarobba MG; Pinotti G; Numico G; Samaritani R; Ciuffreda L; Frassoldati A; Bregni M; Santo A; Piantedosi F; Illiano A; De Marinis F; Tamberi S; Giannarelli D; Delmonte A
Lung Cancer; 2019 Mar; 129():35-40. PubMed ID: 30797489
[TBL] [Abstract][Full Text] [Related]
6. Salvage thoracoscopic resection after nivolumab for stage IV.
Hamaji M; Ozasa H; Yoshizawa A; Date H
Asian Cardiovasc Thorac Ann; 2020 May; 28(4):216-218. PubMed ID: 32276540
[TBL] [Abstract][Full Text] [Related]
7. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N
Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516
[TBL] [Abstract][Full Text] [Related]
8. Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm.
Bover M; Yarza R; Docampo LI
Clin Lung Cancer; 2020 Jan; 21(1):e1-e5. PubMed ID: 31601524
[No Abstract] [Full Text] [Related]
9. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Bott MJ; Yang SC; Park BJ; Adusumilli PS; Rusch VW; Isbell JM; Downey RJ; Brahmer JR; Battafarano R; Bush E; Chaft J; Forde PM; Jones DR; Broderick SR
J Thorac Cardiovasc Surg; 2019 Jul; 158(1):269-276. PubMed ID: 30718052
[TBL] [Abstract][Full Text] [Related]
10. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
Takemoto K; Miyahara N; Chikuie N; Hamamoto T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2019 Oct; 46(5):813-817. PubMed ID: 30442438
[TBL] [Abstract][Full Text] [Related]
12. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
[TBL] [Abstract][Full Text] [Related]
13. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
Cooper DS; Meriggioli MN; Bonomi PD; Malik R
J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
15. Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.
Ando C; Ichihara E; Kano H; Iwamoto Y; Hirabae A; Nakasuka T; Maeda Y; Kiura K
In Vivo; 2019; 33(6):2113-2115. PubMed ID: 31662545
[TBL] [Abstract][Full Text] [Related]
16. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
Sari M; Saip P
J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
18. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
19. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
